Expanding horizons for the targeted management of EGFR-mutant NSCLC

Janssen sponsored industry session at WCLC 2022

Learning objective:         

After watching this broadcast, participants should be able to:

  • Reflect on recent developments in the molecular diagnosis of EGFR-mutant NSCLC
  • Describe updates in the management of advanced EGFR-mutant NSCLC
  • Evaluate the use of novel emerging therapeutic options for EGFR exon 20 insertion mutations and their implementation into clinical practice



  • Martin Reck (Germany)
  • Umberto Malapelle (Italy)
  • Maximilian Hochmair (Austria)
  • Sabine Merkelbach-Bruse (Germany)
  • Jordi Remon (Spain)

More Info
62 Minutes
EM-103048 - Date of preparation: June 2022